Patiala Research Institute Of Diabetes & Eye Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 18-05-2024
- Paid Up Capital ₹ 0.10 M
as on 18-05-2024
- Company Age 4 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 1962.50%
(FY 2022)
- Profit 2047.33%
(FY 2022)
- Ebitda 1895.25%
(FY 2022)
- Net Worth 460.12%
(FY 2022)
- Total Assets 326.79%
(FY 2022)
About Patiala Research Institute Of Diabetes & Eye
The Company is engaged in the Veterinary Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nidhi Aggarwal and Rohit Aggarwal serve as directors at the Company.
- CIN/LLPIN
U85200PB2020PTC051803
- Company No.
051803
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Sep 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Patiala, Punjab, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Patiala Research Institute Of Diabetes & Eye?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nidhi Aggarwal  | Director | 03-Sep-2020 | Current |
| Rohit Aggarwal | Director | 03-Sep-2020 | Current |
Financial Performance and Corporate Structure Insights of Patiala Research Institute Of Diabetes & Eye.
Patiala Research Institute Of Diabetes & Eye Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 1962.5% increase. The company also saw a substantial improvement in profitability, with a 2047.33% increase in profit. The company's net worth Soared by an impressive increase of 460.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Patiala Research Institute Of Diabetes & Eye?
Unlock access to Patiala Research Institute Of Diabetes & Eye's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Patiala Research Institute Of Diabetes & Eye?
Patiala Research Institute Of Diabetes & Eye has a workforce of 0 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Patiala Research Institute Of Diabetes & Eye, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Patiala Research Institute Of Diabetes & Eye's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
